Physician profile
Robert D Rosenberg
NPI 1437110400
$2,680.38
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,619 · 2020: $835 · 2021: $162 · 2022: $44.63 · 2023: $19.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $462.79 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $418.28 | 2019-2022 | |
| Lundbeck LLC | $330.61 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $286.92 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $274.34 | 2019-2022 | |
| Allergan, INC. | $168.66 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $167.32 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $161.08 | 2019-2020 | |
| Alkermes, INC. | $160.67 | 2019-2021 | |
| Abbvie INC. | $68.49 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2021 | |
| Bausch Health US, LLC | $29.99 | 2019-2020 | |
| Noven Therapeutics, LLC | $22.38 | 2020 | |
| Neuronetics, INC. | $19.75 | 2023 | Neurostar Tms Therapy System |
| Vertical Pharmaceuticals, LLC | $16.29 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $16.08 | 2020 | |
| Ironshore Pharmaceuticals INC. | $15.55 | 2019 | |
| Adlon Therapeutics L.P. | $14.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.